Articles related to NEUROLOGICAL DISORDERS

Consider immunosuppressive therapy in patients on adequate acetylcholinesterase inhibitor therapy who do not demonstrate significant benefit. This article discusses the assessment of therapeutic failure, steroidal therapy, when to consider nonsteroidal anti-inflammatory therapy, and recommendations for monitoring treatment.

Leukodystrophies, deficiency-related metabolic diseases, genetic and acquired toxic/metabolic causes, and mitochondrial diseases were identified as the genetic and metabolic disorders of adulthood producing spinal cord signal changes. A number of adult metabolic and genetic illnesses that cause spinal cord atrophy without signal changes have also been discovered. The classification based on spinal MRI results is also offered, along with suggestions for the diagnostic process and alternative diagnoses.

Although the relationship between preceding viral illness and subsequent Guillain-Barre isn’t proven, it is a commonly observed pattern. The severity of GBS ranges from mild sensory disturbances to life-threatening loss of function requiring intubation.

This brief editorial introduces a series of articles describing the medical use of hallucinogens, ketamine, marijuana, and other agents — including the legal and ethical perspectives — in the treatment of various neurologic and psychiatric disorders.

Pregnant women who filled prescriptions for bupropion, citalopram, escitalopram, fluoxetine, or sertraline during pregnancy (antidepressant-exposed cohort) and pregnant women who did not fill an antidepressant prescription within 90 days of the start of their pregnancy through delivery (control group) were the subjects of the study conducted by researchers from Brigham and Women’s Hospital in the United States. The main finding concerned the frequency of ADHD, autism spectrum disorder (ASD), behavioral disorder, developmental coordination disorder, developmental speech or language disorder, intellectual disability, any NDDs, and specific learning disorders among the children of the women in the study.

Basimglurant is a highly selective, potent, and cell-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5). Based on the LibraTN trial — a 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study of basimglurant for trigeminal neuralgia, FDA has granted the molecule Fast Track designation.